Anticancer Pharmaceutical Cyclosporin a Powder Cyclosporin a

Cyclosporin A is a potent and highly selective calcineurin inhibitor class of immunosuppressant produced by fermentation of the fungus Tolypocladium inflatum. Its primary mechanism of action involves binding to intracellular cyclophilin to form a complex that inhibits the activity of calcineurin. This blocks the transcription of key cytokine genes, such as interleukin-2, within T-lymphocytes, thereby specifically suppressing T-cell activation and proliferation and exerting powerful immunosuppressive effects. Clinically, Cyclosporin A is primarily used to prevent and treat rejection following solid organ transplantation (e.g., kidney, liver, heart) and is a cornerstone of transplant immunosuppressive regimens. Additionally, it is employed in the treatment of autoimmune diseases such as severe aplastic anemia, certain types of nephrotic syndrome, severe psoriasis, rheumatoid arthritis, and some forms of uveitis.

Cyclosporin A is a potent cyclic polypeptide immunosuppressant derived from fungal metabolism. Its core mechanism of action lies in selectively inhibiting the activation and proliferation of T lymphocytes. Upon entering cells, Cyclosporin A binds to cyclophilin, a cytoplasmic protein, forming a complex. This complex then binds to and inhibits the phosphatase activity of calcineurin, a key enzyme in the T-cell activation signaling pathway. Inhibition of calcineurin blocks the translocation of nuclear factor of activated T-cells to the nucleus, thereby suppressing the transcription and expression of genes for critical cytokines such as interleukin-2. This specific suppression of cellular immunity has established it as a cornerstone first-line agent for preventing and treating rejection following organ transplantation.